This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk02: was pivotal for Identiv. We were able to complete the sale of our physical security business, providing significant working capital. This is key as it allows management to focus solely on building our IoT business. Concurrently, in Q3, we were able to make significant progress towards our strategic growth plan and the transition of production from Singapore to Thailand. Third quarter 2024 revenue was $6.5 million, $0.4 million above the upper range of our guidance, and a decrease of $5.2 million compared to the prior year period. The decrease in GAAP revenue year over year was primarily the result of lower sales of BLE transponder and mobile product. Third quarter gap and non-gap gross margin in Q3 2024 was 3.6% and 9.3% respectively compared to gap and non-gap gross margin of 11.2% and 14% respectively in Q3 2023. The decrease in gross profit margins was primarily attributable to lower sales as previously discussed. which resulted in the underutilization of our production facilities in Southeast Asia. As Kirsten also mentioned, by focusing our growth efforts on higher margin opportunities in healthcare and other high-value segments, we believe we can achieve a long-term 35% non-GAAP gross margin. GAAP and non-GAAP operating expenses for the third quarter of 2024, including research and development, sales and marketing, and general and administrative costs totaled $9.8 million and $5.1 million, respectively, as compared to $4.6 and $4.1 million, respectively, in Q3 2023. Third quarter GAAP operating expenses included $3.6 million in strategic transaction-related costs and $1.1 million in stock-based compensation. Third quarter gap net loss from continuing operations was $9.3 million or $0.40 per basic and diluted share. Compared to gap net loss from continuing operations of $3.7 million or $0.17 per basic and diluted share in the third quarter of 2023, the year-over-year increase in our net loss was primarily related to our strategic review costs and an increase in stock-based compensation costs incurred in Q3 2024. Non-GAAP adjusted EBITDA loss for Q3 2024 was $4.5 million compared to $2.3 million in the third quarter of 2023. The increase was primarily the result of our lower year-over-year IoT revenues, which also resulted in the underutilization of our production facilities in Southeast Asia. In the appendix of today's presentation, we have provided a full reconciliation of GAAP to non-GAAP financial information, which is also included in our earnings release. Turning to the balance sheet, we exited Q3, 2024 with 145.7 million in cash, cash equivalents and restricted cash. An increase of 121.4 million since December 31st, 2023. In the nine months ended September 30th, 2024, the increase in cash was a result of 143.4 million from investing activities, primarily as a result of our strategic transaction Offset in part by $11.7 million used in financing activities, which included $10 million for the repayment of our credit facility and $1.6 million in taxes paid on the settlement of RSU releases and $10.4 million used in operating activities. Our working capital exiting Q3 2024 was $147 million. We strengthened our balance sheet, positioning us to pursue our organic and inorganic growth initiatives. Kirsten will be discussing our overall capital allocation framework, including our $10 million share repurchase program announced today. As of September 30th, our expected net operating cash use over the next 12 months is in the range of $14 to $16 million, excluding an estimated tax payment of $7 million related to our asset sales and any share repurchase activity. In our 10Q filing, we will be providing a full reconciliation of the year-to-date cash flows. For completeness, we have included the full balance sheet in the appendix of today's earnings release. Lastly, our financial outlook. For Q4 2024, we currently expect revenue from our IoT business to be in the range of $6.0 to $6.3 million. This concludes the financial discussion. I'll now pass the call back to Kirsten.
spk03: Thanks, Justin. So with that financial context, I'd like to dive into our new growth strategy and why we believe Identiv is uniquely positioned to execute this strategy. Underpinning our strategy are several strong macro trends that are driving demand for RFID and next-generation technologies like BLE. These include digitization and IoT expansion, enhanced security and anti-counterfeiting, regulatory compliance and safety, and sustainability in the circular economy. The digital identification of products through RFID and BLE helps link physical assets with digital systems, which provides users with compelling benefits, such as real-time tracking and visibility, enhanced product security and authentication, and engaging customer experiences. Furthermore, the data generated by RFID is being integrated into advanced analytics and artificial intelligence models, which enables improved decision making across industries, increasing RFID's value proposition. As the number of RFID-enabled applications multiplies, These emerging use cases often demand new and more complex solutions to ensure their success and ultimately strong market adoption. We believe IDENTIF is uniquely positioned to support these types of complex requirements with our industry-leading innovation in highly engineered inlay design, rapid prototyping capabilities, and strong multi-component engineering and manufacturing capabilities. To allow us to fully capitalize on the opportunities across multiple verticals, we will deploy our new perform, accelerate, and transform growth strategy to drive revenue and EBITDA expansion. Perform, accelerate, and transform is a framework that we will implement beginning in quarter one 2025 to strengthen and optimize the performance of our core channel business, accelerate our growth, and ultimately transform the business. First, Perform is focused on strengthening, optimizing, and growing our core channel business. The objective of Perform is to grow our market share and increase our profitability in the channel. We will focus on higher margin opportunities with our existing customers and channel partners, expand growth margins by completing the transition to Thailand, execute our MPD projects with discipline, and delight our customers with excellent customer support and timely product delivery. We are implementing a stage-gate process to carefully manage our MPD project pipeline, which is designed to focus our time and R&D resources on the projects with the highest probability of success and discontinue those that we deem financially or technically unviable. We will be implementing clear metrics to monitor our progress with our core business performance. We plan to disclose several new metrics on our quarter four earnings call. Second, Accelerate is focused on specific initiatives to spur accelerated growth, each with a compelling return on investment. We have identified three distinct initiatives to accelerate growth. One related to developing business within healthcare, a second related to developing business within three high-value applications outside of healthcare, and a third related to expanding our BOE and multi-component technology platform. Our Healthcare Growth Initiative will be led by a market and business development team to pursue end customers directly as opposed to through the channel. This team will focus on three priority areas. medication adherence for home use drug delivery devices, consumable authentication for medical devices and diagnostic test equipment, and condition monitoring for biologics and clinical specimens. We have confirmed through primary and secondary market research that each of these areas have significant unmet needs and a meaningful addressable market that can be addressed through RFID and BLE solutions. For example, medication non-adherence has been cited at up to 40% to 50% in chronic conditions in the U.S., causing nearly $100 billion in preventable medical costs per year. Collectively, across these three priority areas, the total addressable volume is over 10 billion units annually, or roughly $1.5 to $2 billion in RFID and BLE inlay sales. The second growth initiative will focus on non-healthcare high-value segments. We intend to address three specific use cases, inventory management for plastic pallets and bins to support recycling initiatives mandated by retailers, smart packaging for luxury products to combat counterfeiting, and home device consumable authentication to reduce counterfeiting and ensure proper assembly and use. Through our channel partnerships, we have early traction in each of these use cases and can see the value that RFID and BOE provides. The EU's forthcoming digital product passport regulations also provide some significant tailwinds for growth in these areas. Similar to the healthcare initiative, a segment-specific market and business development team will be established to secure new partnerships and serve end customers. The third growth initiative is expansion of our BLE and multi-component technology platform. BLE is a next-generation technology for IoT, providing benefits for certain applications that are challenging to address with traditional RFID technologies. Gartner recently named ambient invisible intelligence, made possible by BLE, as one of the top tech trends for 2025. We intend to continue expanding our BLE capabilities and technologies through our current MPD projects, such as the ongoing pilot programs with Energist utilizing the Williott BLE technology, our new partnership with InPlay, Williott's go-to-market efforts with big box retailers, as well as our own go-to-market strategy within healthcare. As with PERFORM, We plan to disclose accelerate specific metrics for tracking progress on these three growth initiatives on our quarter four 2024 earnings call. The third part of our strategic framework is transform. This pillar focuses on driving significant business expansion and capability growth through M&A. M&A is an important component of our growth strategy and is intended to enable us to expedite achieving EBITDA break even. We are assessing potential tuck-in M&A opportunities that fit our growth strategy and acquisition guidelines. We intend to focus on targets that not only bring scale, but are also accretive financially and bring strong synergies, additive talent, and complementary products. In a nutshell, our ideal tuck-in target is a company with 5 to 30 million in annual revenue, that's EBITDA positive, ideally with EBITDA margins greater than 10% and has a valuation of less than 10 times EBITDA post synergies and between one to two times revenue depending on profitability. Adding scale and capabilities and increasing utilization of our state of the art time facility are our near term priorities. Moving on to capital allocation. Our capital allocation plan is designed to utilize a portion of our transaction proceeds for targeted investments that align with our perform, accelerate, and transform strategic framework and will drive our future growth. As I stated earlier, our total net proceeds from the transaction are approximately $135 million. Our first priority is to invest in organic growth. Our current plan is to allocate 25% to 30% of the net proceeds for investing in our core business and key growth initiatives, the perform and accelerate parts of our PAT framework. We are currently targeting 35% to 40% for strategic M&A, the transform part of our strategic framework, and 25% to 30% is currently targeted for future working capital purposes. End. The final component, as announced today, is a $10 million stock repurchase program. I'd like to now turn the call over to our chairman, Jim Owsley, for an overview of our share repurchase program, as well as the board's recommendations for updating IDENTIS corporate governance. Jim, over to you.
spk01: Thank you, Kirsten. Given the significant transformation underway at IDENTIS, the Board of Directors has decided this was the appropriate time to review our corporate governance policy to better align with the company's new strategic direction and the interest of our shareholders. Pending final approval, the Board intends to recommend the following updates to Identiv's corporate governance policies and procedures. First, solicit stockholder approval at the 2025 Annual Meeting to eliminate our classified board structure. Secondly, In uncondested elections, the board would consider the resignation of any director who does not receive a majority vote. And third, amend our equity compensation plan to eliminate the ability to reprice options without prior stockholder approval. We are taking two additional important actions. We are actively recruiting board of director candidates with deep additive expertise that will be valuable in guiding us through this transition. And lastly, the board of directors has approved a share repurchase program, authorizing the company to purchase up to $10 million of its common stock. This strategic move reflects the board's confidence in the new growth strategy and the strong conviction that Identiv's current share price is undervalued relative to its long-term opportunity. We think these corporate governance changes are in the best interest of Identiv and our stockholders. We look forward to providing you much more detail in the future. I will now turn it back to Kirsten. Thank you.
spk03: Thanks, Jim. In conclusion, we have been and continue to see strong macro trends that are driving robust demand for RFID and next-generation technologies. This demand provides IDENTIF the tailwinds to grow and reach profitability. IDENTIF's long track record of innovation is widely recognized. We have the right capabilities and RFID-related technology required for emerging applications across several high-value verticals. And we now have ample financial resources that we believe will allow us to execute our perform, accelerate, and transform strategy and drive meaningful returns and shareholder value. The leadership team has taken significant steps towards transforming identities, and we believe the company is well positioned to capitalize on the exciting opportunities ahead. With that, I'd like to open the call for your questions. Operator, please open the question queue.
spk00: Thank you. At this time, we will be conducting a question and answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you'd like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please, while we poll for questions. Once again, please press star one on your touchtone phone to ask a question.
spk03: Thanks, Operator, and thank you all again for joining us today. We appreciate the continued support of our employees, partners, and shareholders. In the coming months, we'll be prioritizing investor outreach, meeting with existing and prospective investors to present our new growth strategy and capital allocation plan and objectives. For today's Q&A, in addition to Justin and me, we have our Chairman of the Board, Jim Owsley, Amir Khoshnayati, and Manfred Mueller. So, Operator, let's please proceed with questions.
spk00: Absolutely. Thank you. The first question comes from Craig Ellis with B. Reilly Securities. Please proceed.
spk04: Hi, this is Daisy Cheung for Craig. And thanks for taking the question, Kristen. Congratulations on the great first quarter without the premises business. And I just have a quick question about how do you think about when we think about about the near-term confidence in attaining the 27% plus or 25% plus non-GAAP gross margin in mid-2025 if that timeline has changed since the last time. Thank you.
spk03: Yeah, no, so as I mentioned, we're making great progress with the transition of our production from Singapore to Thailand. The team is working really hard. Our customers are partnering with us to make sure that We can qualify the new site and get their production moved. So it's going very smoothly. So as I said, we anticipate about 75% to be transitioned by the end of this year. We have a couple of remaining customers that will go into the first half of next year. So we're feeling very confident that we'll be all the way through the transition for sure by the end of 2025. Now, of course, we need to give our team there a little bit of time to get up to speed. to learn all the ins and outs of the production, but as soon as they've reached their full productivity, we feel confident in the 26 to 28 percent non-GAAP growth margin range.
spk04: Got it. Thank you. And if I can have a follow-up question on maybe the cash burn intensity that we discussed before. When we think about the trajectory of the fiscal one year of $15 million or the following year, $25 million. Is that still within our plan? And how do we think about that when we're trying to discuss the passive profitability for the company?
spk02: This is Justin. Happy to answer the question. Can you rephrase what you meant when you said $25 million? I wasn't following that. We did put out, just to answer your quick question, I think that we did put out 14 to 16 million over the next 12 months. We feel pretty strongly that that is a good number and similar to what we had said last quarter as well. So we're confident in the 14, 16 for the next 12 months, but I wasn't sure what you meant by the 25 million that you referenced.
spk04: Yeah, it's just the following year if that's within the range that you're thinking about, about the 25.
spk02: Well, we don't give guidance post, we wouldn't give cash burden guidance past the next four quarters. But no, it would not be 25 million the following year. So I think that is too high.
spk04: Okay. Okay, got it. Yeah. Okay. And if I can just squeeze in one more. Thank you, Justin.
spk02: Of course.
spk04: So when we, thank you for breaking down, you know, the capital allocation. It's very helpful. When we think about during the M&A, is there a potential acquisition timing that you think could help you get to the 65 million in revenue?
spk03: Yes. I mean, we are actively looking at potential acquisition targets now. And obviously, that is one of our three strategic targets. pillars and definitely we're doing that assessment now. So, it is a priority. We don't have any specific timing or timeline in place at this point, but it is something that we are actively looking at.
spk05: Got it. Thank you.
spk00: Once again, if you have a question or a comment, please indicate so by pressing star 1 on your touchtone phone. Okay, we have a follow-up coming from Craig Ellis with B. Reilly. Please proceed.
spk04: Hi. Hey, guys. Sorry, I guess I just have one more. So can you talk about any potential large pharmaceutical companies penetration within the medical and, you know, given the strong relationship that Addentive has had previously and given Kirsten's strong background coming from the area?
spk03: Yeah, so certainly pharmaceuticals, definitely an interesting area for us. We have active MPD projects underway. They're still in the MPD process, so new product development process, and we're working collaboratively to come up with solutions. We also, this is an area that is an area of focus for us. as we are building our new business development and marketing development team. So, it's definitely an area that we're going to also look for additional opportunities. So, definitely a strong area of interest and, you know, we have a decent amount of activity underway working on projects to support that area.
spk04: Got it. Thank you.
spk00: Okay. I'd now like to turn the floor back to management for any closing remarks.
spk03: Well, thank you again for joining us. We really do appreciate it. As I mentioned before, we will be prioritizing investor outreach. And we have coming up the Craig Hallam Alpha Select Conference in New York in November. We'll be at the Imperial Capital Security Investors Conference in December. And we're definitely looking forward to speaking and meeting many of our investors in the coming months. Thank you all very much.
spk00: Thank you. This concludes today's conference, and you may disconnect your lines at this time. Thank you for your participation.
Disclaimer